Nishina Sohji, Hino Keisuke, Korenaga Masaaki, Vecchi Chiara, Pietrangelo Antonello, Mizukami Yoichi, Furutani Takakazu, Sakai Aya, Okuda Michiari, Hidaka Isao, Okita Kiwamu, Sakaida Isao
Department of Gastroenterology and Hepatology, Yamaguchi University Graduate School of Medicine, Yamaguchi, Japan.
Gastroenterology. 2008 Jan;134(1):226-38. doi: 10.1053/j.gastro.2007.10.011. Epub 2007 Oct 9.
BACKGROUND & AIMS: Despite abundant clinical evidence, the mechanisms by which hepatic iron overload develops in patients with hepatitis C virus (HCV)-associated chronic liver disease remain unknown. The aim of this study was to investigate how hepatic iron overload develops in the presence of HCV proteins.
Male transgenic mice expressing the HCV polyprotein and nontransgenic control mice (C57BL/6) were assessed for iron concentrations in the liver, spleen, and serum and iron regulatory molecules in vivo and ex vivo.
Transgenic mice had increased hepatic and serum iron concentrations, decreased splenic iron concentration, and lower hepcidin expression in the liver accompanied by higher expression of ferroportin in the duodenum, spleen, and liver. In response to hepatocellular iron excess, transferrin receptor 1 expression decreased and ferritin expression increased in the transgenic liver. Transgenic mice showed no inflammation in the liver but preserved the ability to induce hepcidin in response to proinflammatory cytokines induced by lipopolysaccharide. Hepcidin promoter activity and the DNA binding activity of CCAAT/enhancer-binding protein alpha (C/EBP) were down-regulated concomitant with increased expression of C/EBP homology protein, an inhibitor of C/EBP DNA binding activity, and with increased levels of reactive oxygen species in transgenic mice at the ages of 8 and 14 months.
HCV-induced reactive oxygen species may down-regulate hepcidin transcription through inhibition of C/EBPalpha DNA binding activity by C/EBP homology protein, which in turn leads to increased duodenal iron transport and macrophage iron release, causing hepatic iron accumulation.
尽管有大量临床证据,但丙型肝炎病毒(HCV)相关慢性肝病患者肝铁过载的发生机制仍不清楚。本研究的目的是探讨在存在HCV蛋白的情况下肝铁过载是如何发生的。
对表达HCV多聚蛋白的雄性转基因小鼠和非转基因对照小鼠(C57BL/6)进行体内和体外肝脏、脾脏及血清中铁浓度以及铁调节分子的评估。
转基因小鼠肝脏和血清铁浓度升高,脾脏铁浓度降低,肝脏中血浆铁调素表达降低,同时十二指肠、脾脏和肝脏中铁转运蛋白表达升高。在转基因肝脏中,肝细胞铁过量时,转铁蛋白受体1表达降低,铁蛋白表达增加。转基因小鼠肝脏无炎症,但保留了对脂多糖诱导的促炎细胞因子作出反应而诱导血浆铁调素的能力。在8个月和14个月龄的转基因小鼠中,血浆铁调素启动子活性以及CCAAT/增强子结合蛋白α(C/EBP)的DNA结合活性下调,同时C/EBP同源蛋白(一种C/EBP DNA结合活性抑制剂)表达增加,活性氧水平升高。
HCV诱导的活性氧可能通过C/EBP同源蛋白抑制C/EBPα DNA结合活性来下调血浆铁调素转录,进而导致十二指肠铁转运增加和巨噬细胞铁释放,引起肝脏铁蓄积。